NeoChord, Inc. Appoints New Chief Executive Officer to Lead Commercialization Efforts and Study Novel First-Line Therapy for Mitral Valve Regurgitation
07.08.2025 - 18:03:45Degenerative mitral valve disease is the third most common cardiovascular disease in both Europe and the United States. The prevalence of severe mitral valve regurgitation is estimated at 3-5M patients but less than 3% of these patients are receiving proper treatment due to the invasiveness of arrested, open-heart surgery. Degenerative mitral valve disease is the most common cause of mitral regurgitation with a main etiology of leaflet prolapse due to elongated or ruptured chordal support. The mitral valve chords are the primary physiologic support mechanism that prevents the leaflet prolapse which results in regurgitation. The ideal therapy for patients with degenerative mitral valve regurgitation is early intervention to restore normal chordae function. Minimally invasive delivery of neochordae allows the most physiologic restoration of regurgitation without limiting any future valve treatment options.
About NeoChord
NeoChord is the world leader in beating heart mitral valve chordal repair with a portfolio of commercial and clinical product technologies. The DS1000 transapical (TA) chord repair system is commercially marketed in Europe and has been used to place more than 5,000 successful neochordae in over 2,000 patients. NeXus is a transseptal (TS) chord repair system that incorporates the same proprietary suture-based anchor elements proven in the DS1000 experience and is currently in feasibility clinical trials.
For more information, please visit www.neochord.com
Logo - https://mma.prnewswire.com/media/2344969/NeoChord_Logo.jpg
View original content:
